To overcome this weakness and to improve cardiotoxic and/or endocrine side-effect-free antitumor activity, more stable drug-linkers (e.g., oxime bond) and more tumor-selective GnRH analogs could be advantageous. The gene discussed is GNRH1; the disease is neoplasm.